Across TCGA pan-cancer cohorts, FAM3C mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated FAM3C data layer compared with 25 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher FAM3C mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated FAM3C expression acts as an unfavorable survival marker, although some lineages such as HNSC and GBM show a favorable association.

CCRCC, HNSC, and PDAC are the cancer types where FAM3C mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	0.737	0.937	.002	39	view →
HNSC	DFS	Quartile	All	0.948	0.772	.010	11	view →
PDAC	DFS	Median	IV	0.214	0.785	.006	9	view →
LSCC	DFS	Quartile	All	0.426	1.000	.026	8	view →
LUAD	DFS	Median	III,IV	0.409	0.941	.010	5	view →
GBM	OS	Tertile	All	0.969	0.735	.013	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

Exploration

Same gene, other analysis: FAM3C tumor-vs-normal RNA expression · all FAM3C data types